Fate Therapeutic Stock Price, News & Analysis

Fate Therapeutics (NASDAQ: FATE) announced its participation in two upcoming investor conferences. The Barclays Global Healthcare Conference is scheduled for March 11, 2021, from 11:30 AM to 11:55 AM ET, followed by the Oppenheimer Virtual 31st Annual Healthcare Conference on March 17, 2021, from 1:10 PM to 1:40 PM ET. Both presentations will be available via live webcast on the Company's website under 'Events & Presentations.' Fate Therapeutics focuses on cellular immunotherapies for cancer and is currently developing innovative therapies including natural killer cell and T-cell immunotherapies.

Fate Therapeutics reported promising interim data from its FT516 Phase 1 study, showing objective responses, including two complete responses in 3 of 4 patients with relapsed/refractory B-cell lymphoma. FT596 demonstrated clinical activity in refractory DLBCL with a partial response in one patient. The FDA allowed the IND application for FT576, the first cell therapy engineered with four anti-tumor modalities. As of December 31, 2020, Fate held over $482 million in cash and investments and generated $15.9 million in revenue for Q4 2020, with R&D expenses of $39 million.

Fate Therapeutics, a clinical-stage biopharmaceutical company focused on cancer immunotherapies, will present at the 10th Annual SVB Leerink Healthcare Conference on February 25, 2021, at 5:00 p.m. EST. The live webcast can be accessed on the company's website, with an archived version available after the event. Fate specializes in developing first-in-class cellular immunotherapies using its proprietary induced pluripotent stem cell (iPSC) platform, targeting tumor-associated antigens and enhancing existing cancer treatments.

Fate Therapeutics will host a conference call on February 24, 2021, at 5:00 p.m. ET to discuss its Q4 and full year 2020 financial results and provide a corporate update. The call can be accessed by dialing 877-303-6235 (domestic) or 631-291-4837 (international) with conference ID 6368962. Additionally, a live audio webcast will be available on the company's website, with an archived version accessible two hours post-event. Fate Therapeutics focuses on programmed cellular immunotherapies for cancer and holds a leadership position in the development of universal iPSC cell products.

Fate Therapeutics (NASDAQ: FATE) has completed an underwritten public offering, raising approximately $432 million. The offering included 5,122,807 shares at $85.50 each, along with pre-funded warrants for 257,310 shares. The funds will support clinical trials, manufacturing operations, and general corporate purposes. The company aims to enhance its cellular immunotherapies targeting cancer and immune disorders, leveraging its iPSC product platform.

Fate Therapeutics announced a public offering of 4,421,053 shares of common stock at $85.50 each, along with pre-funded warrants for 257,310 shares at $85.499, raising approximately $400 million. The expected net proceeds are about $376 million after expenses. The funds will support clinical trials, product manufacturing, and general corporate purposes. The offering is set to close by January 8, 2021, pending customary conditions. Jefferies, BofA Securities, SVB Leerink, and Barclays are managing the offering.

Fate Therapeutics announced a public offering of $350 million in common stock, intending to utilize the net proceeds for critical activities including clinical trials, manufacturing operations expansion, and preclinical research. An additional $52.5 million option may be granted to underwriters. The offering is contingent on market conditions and will be executed under an existing shelf registration with the SEC. This strategic move aims to bolster Fate's pipeline of cellular immunotherapies for cancer and immune disorders.

Fate Therapeutics announced positive results from its Phase 1 clinical trial of FT596, an off-the-shelf NK cell therapy targeting CD19, at the Society of Hematology meeting. A heavily pre-treated patient with DLBCL achieved a partial response after administering a single dose of 30 million cells. A second treatment cycle led to a deepening response, with no serious adverse events or cytokine release syndrome reported. The duration of response was 3.8 months, comparable to autologous CAR-T therapies. The trial continues to explore higher doses and combinations.

Fate Therapeutics announced positive interim results from its Phase 1 study of FT516 in combination with rituximab for relapsed/refractory B-cell lymphoma. Of the four patients evaluable, three achieved an objective response, including two complete responses. Importantly, FT516 was well-tolerated with no severe adverse events and no cases of cytokine release syndrome. The study indicates the potential for FT516 to be administered in an outpatient setting, potentially expanding treatment options for patients. A fourth dose cohort of FT516 is planned as part of ongoing research.